Treatment of refractory and relapsed Hodgkin's disease: Intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support

David D. Hurd(Duke University), Clara D. Bloomfield(North Shore University Hospital), Neal P. Christiansen(University of Minnesota), B. A. Peterson(Australian National University), Daniel J. Weisdorf(University of Minnesota), Ellis Levine(University of Maryland, Baltimore), Philip B. McGlave(University of Minnesota), Robert J. Haake(University of Minnesota), Tae Hyong Kim(Yonsei University), Larry C. Lasky(Cleveland State University), Bruce Bostrom(Minnesota West Community & Technical College)
Medical and Pediatric Oncology
January 1, 1990
10.1002/mpo.2950180603
Cited by 24

Related Papers

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
|Blood|2009|3.4k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k